Catalyst Bio shares bashed as neutralizing antibodies force investigators to freeze hemophilia cohort work
Shares of Catalyst Biosciences $CBIO were badly damaged in the wake of an alert that two patients in one cohort of their early-stage hemophilia drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
